The Roles of Glut5 in Imatinib Resistance in the Ph+ Acute Lymphoblastic Leukemia Cell

YAN Tian-you, NAREN Duo-lan, GONG Yu-ping

Abstract

To explore the possible roles of glucose transport 5 (Glut5) in imatinib resistance in the Ph+ acute lymphoblastic leukemia cell (Ph+ ALL). Methods The gene chip technique was used to detect different gene expression between Ph+ ALL cell line SUP-B15/R (imatinib resistant cell line) and SUP-B15/S (imatinib sensitive cell line), the gene of solute carrier family 2 member 5 (SLC2A5) and its coded protein Glut5 were screened out and were reconfirmed by qPCR and Western blot assay. The imatinib half maximal inhibitory concentration (IC50) to SUP-B15/S cells with or without fructose treatment was further detected by MTT assay, simultaneously signal pathway gene was detected by qPCR assay. Results Metabolism related gene SLC2A5 was screened out with gene chip technique and the Western blot assay and qPCR confirmed the high expression of SLC2A5 gene and its coded protein Glut5 in SUP-B15/R cells. IC50 values of imatinib to SUP-B15/S cells after treatment with 25 μmol/L fructose were increased from (44.50±2.38) μmol/L to (64.71±1.69) μmol/L, in the meanwhile, PI3K and AKT mRNA level also increased in fructose treated SUP-B15/S cells compared to the control. Conclusions High expression of SLC2A5 and Glut5 protein in SUP-B15/R cells leads to increased fructose absorption, and further activates PI3K/AKT pathway which cause the SUP-B15 cell resistance to imatinib.

 

Keywords: Ph+ acute lymphoblastic leukemia, Imatinib resistance, Glucose transport 5, Fructose 

 

Full Text:

PDF


References


FORGHIERI F, LUPPI M, POTENZA L. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology,2015,20( 10);618-619.

ANDREUEJ. LLEDO E, POCH E. et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kipl degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res, 2005,65( 8): 3264- 3272.

MANLEY PW, COWAN-JACOB SW, BUCHDUNGER E. et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer,2002,38(Suppl 5):S19- S27.

GORREME, MOHAMMED M, ELLWOOD K. et al. Clinical resistance to STI-571 cancer therapy caused by BCR- ABL gene mutation or amplification. Science, 2001, 293 (5531):876-880.

SHAH NP, NICOLL JM, NAGAR B, et al. Multiple BCR- ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2002,2(2):117-125.

VON BUBNOFF N, SCHNELLER F, PESCHEL C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571; a prospective study. Lancet,2002,359(9305) :487-491. GORREME.

ELLWOOD-YEN K. CHIOSIS G, et al. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood,2002,100(8):3041-3044.

HOFMANN WK, DE VOS S, ELASHOFF D, et al. Relation between resistance of Philadelphia-chromosome- positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles; a gene- expression study. Lancet,2002,359(9305);481-486.

BO AG JM, BEESLEY AH. FIRTH MJ. et al. Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia,2006 .20(10): 1731-1737.

RIVENZON-SEGAL D, RUSHKIN E, POLAK-CHARCON S, et al. Glucose transporters and transport kinetics in retinoic acid-differentiated Т47D human breast cancer cells. Am J Physiol Endocrinol Metab.2000,279(3) ;E508-E519. GABY AR. Adverse effects of dietary fructose. Ahern Med Rev,2005,10(4):294-306.

LIU H. HUANG D. MCARTHUR DL, et al. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res,2010,70(15) ;6368-6376.

KUMAMOTO R. UTO H, ODA K, et al. Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat. Eur J Med Res, 2013, 8; 54 [2016-10-15]. http;//www. eurjmedres. com/content/18/1/54. doi:10. 1186/2047-783X-18-54.

AUNE D, CHAN DS, VIEIRA AR, et al. Dietary fructose, carbohydrates, glycemic indices and pancreatic cancer risk; a systematic review and meta-analysis of cohort studies. Ann Oncol,2012,23( 10) :2536-2546.

ZAMORA-LEON SP, GOLDE DW, CONCHA II, et al. Expression of the fructose transporter GLUTS in human breast cancer. Proc Natl Acad Sci U S A, 1996,93(5) ; 1847- 1852.

SHU R, DAVID ES, FERRARIS RP. Luminal fructose modulates fructose transport and GLUT-5 expression in small intestine of weaning rats. Am J Physiol, 1998,274(2 Pt 1); G232- G239.

CUI XL. SCHLESIER AM, FISHER EL, et al. Fructose- induced increases in neonatal rat intestinal fructose transport involve the Pl3-kinase/Akt signaling pathway. Am J Physiol Gastrointest Liver Physiol,2005,288(6) :G1310-G1320.

BURANT CF. SAXENA M. Rapid reversible substrate regulation of fructose transporter expression in rat small intestine and kidney. Am J Physiol. 1994 ,267 ( 1 Pt 1);G71- G79.

CLARK PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009,76(9) : 939-945.

RAY R, CHEN G, VANDE-VELDE C, et al. BNIP3 heterodimerizes with Bcl-2/Bcl-X ( L) and induces cell death independent of a Bcl-2 homology 3(BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem.2000. 275(2):1439-1448.

ZHANG H. BOSCH-MARCE M. SHI MOD A LA, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem, 2008,283 ( 16) ; 10892-10903.

GUO K, SEARFOSS G.KROLIKOWSKI D. et al. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ,2001,8(4);367-376.

ERKAN M. KLEEFFJ, ESPOSITO 1, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene,2005.24 (27);4421-4432.

GUNARATNAM L, MORLEY M. FRANOVIC A. et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(— /— ) renal cell carcinoma cells. J Biol Chem,2003,278(45) ;44966-44974.

MURAI М, TOYOTA М. SUZUKI Н. Et al. Aberrant methylation and silencing of the BNIP 3 gene in colorectal and gastric cancer. Clin Cancer Res,2005,11(3); 1021-1027.

BACON AL, FOX S, TURLEY H. et al. Selective silencing of the hypoxia-inducible factor 1 target gene BN IP3 by histone deacetylation and methylation in colorectal cancer. Oncogene,2007,26(1):132-141.

PARK КС, HEO JH. JEON JY, et al. The novel histone deacetylase inhibitor, N-hydroxy-7-( 2-naphthylthio ) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells. BMC Cancer, 2015, 15: 19 Г 2017-02-20]. https;//bmccancer. biomedcentral. com/articles/10. 1186/ sl2885-014-1003-l. doi: 10. 1186/sl2885-011-1003-1.

SANTOS N, WENGER JB, HAVRE P, et al. Combination therapy for renal cell cancer; what are possible options? Oncology ,2011,81(3/4); 220-229.


Refbacks

  • There are currently no refbacks.